Hepatitis C - MIGENIX Inc. (MGI.TO) Second Quarter Fiscal 2006 Financial Results Conference Call & Web Cast Notification

MIGENIX Inc. (MGI.TO) Second Quarter Fiscal 2006 Financial Results Conference Call & Web Cast Notification
BioSpace - include drug candidates for the treatment of chronic Hepatitis C infections (Phase II), the prevention of catheter

Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Com
Canada NewsWire - Results Reported at American Association for the Study of Liver Diseases (AASLD) Meeting Large Phase II Combination Study Under Way SAN FRANCISCO, Nov. representing an area of great unmetmedical need. Chronic hepatitis C affects more than 10 million people inmajor world

MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical Study of Celgosivir
BC Technology - glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus infections the success of treatment for patients suffering from chronic hepatitis C infections

Biolex Therapeutics Announces Initiation of Phase 1 Clinical Study of Hepatitis C Candidate Locteron(TM)
Drug News Wire - for the treatment of patients with chronic hepatitis C. Locteron combines BLX-883, a standard treatment for patients with chronic hepatitis C is pegylated alfa interferon